simon israeli
  • Simon Daniel Israeli-Korn, MBBChir (MD), MRCP, PhD

  • Department: Neurology
  • Specialties: Neurology
  • Language: Hebrew, English, Spanish, French
  • Request Consultation

About Me

Dr. Simon Israeli-Korn is a specialist in Movement Disorders, graduated from Cambridge University in England and completed his residency in Neurology at the Sheba Medical Center.

He then completed his PhD in the field of Movement Science at the Weizmann Institute of Science in the MD-PhD track for medical specialists. During this time, he worked in the Movement Disorders Institute at Sheba gaining subspecialty expertise in Movement Disorders and Deep Brain Stimulation.

Upon returning to Sheba full-time he continued to work in the Movement Disorders Institute and took a leading role in advancing the ground-breaking focused ultrasound treatment for tremor. He is an attending physician in the Neurology Department and continues to pursue his academic and research interests relating to Movement Disorders and Movement Science involving collaborations with both academia and industry.

Over the last 7 years Dr. Israeli-Korn has attained extensive experience in all aspects of the surgical treatment of movement disorders (in particular, Parkinson’s Disease, dystonia and tremor).

  • Senior Physician in the Neurology Department, Sheba Medical Center
Conditions and treatment
  • Parkinson's Disease
  • Essential Tremor
  • Dystonia
  • Normal Pressure Hydrocephalus
  • Progressive Supranuclear Palsy
  • Multiple System Atrophy
  • Corticobasal degeneration
  • Lewy Body Dementia
  • Freidreich's ataxia
  • Neurodegeneration with Brain Iron Accumulation Disorders
  • Hereditary movement disorders
  • Deep brain stimulation for movement disorders
  • Focused ultrasound thalamotomy for tremor
  • Botulinum toxin ("botox") injection to the facial, neck and limb muscles for movement disorders, including for under 18 year-olds


Education and Training
  • MBBChir (MD equivalent) from the University of Cambridge, England, UK
  • USMLE: Steps 1 and 2
  • MRCP: Postgraduate training in Internal Medicine
  • Residency in Neurology at the Sheba Medical Center at Tel Hashomer
  • PhD in Movement Science at the Weizmann Institute of Science
  • Subspecialty training in Movement Disorders at the Sheba Medical Center at Tel Hashomer
Board Certifications
  • Neurology


  1. Yahalom G, Cohen OS, Warmann-Alaluf N, Shabat C, Strauss H, Elincx-Benizri S, Israeli-Korn S, Stein E, Greenbaum L, Hassin-Baer S. The impact of early versus late levodopa administration. Journal of Neural Transmission (2016); 21: 1-6.
  2. Greenbaum L, Israeli-Korn SD, Cohen OS, Elincx-Benizri S, Yahalom G, Kozlova E, Strauss H, Molshatzki N, Inzelberg R, Spiegelmann R, Israel Z. The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson’s disease. Parkinsonism & related disorders (2013); 19: 1053-6.
  3. Israeli-Korn SD, Hocherman S, Hassin-Baer S, Cohen OS, Inzelberg R. Subthalamic Nucleus Deep Brain Stimulation does not Improve Visuo-Motor Impairment in Parkinson’s Disease. PLoS One (2013); 8(6): e65270
  4. Inzelberg R, Afgin AE, Massarwa M, Schechtman E, Israeli-Korn SD, Strugatsky R, Abuful A, Kravitz E, Farrer LA, Friedland RP. Prayer at Midlife is Associated with Reduced Risk of Cognitive Decline in Arabic Women. Curr Alzheimer Res. (2013); 10: 340-6
  5. Afgin AE, Massarwa M, Schechtman E, Israeli-Korn SD, Strugatsky R, Abuful A, Farrer LA, Friedland RP, Inzelberg R. High Prevalence of Mild Cognitive Impairment and Alzheimer’s Disease in Arabic Villages in Northern Israel: Impact of Gender and Education.  J Alzheimers Dis. (2012); 29: 431-9
  6. Bentley P, Rosso M, Sadnicka A, Israeli-Korn S, Laffan M, Sharma P. Intravenous immunoglobulin increases plasma viscosity without parallel rise in blood pressure. J Clin Pharm Ther. (2011); 37: 286-90
  7. Hassin-Baer S, Hattori N, Cohen OS, Massarwa M, Israeli-Korn SD, Inzelberg R. Phenotype of the 202 adenine deletion in the parkin gene: 40 years of follow-up. Mov Disord.(2011); 26: 719-22
  8. Israeli-Korn SD, Schwammenthal Y, Yonash-Kimchi T, Bakon M, Tsabari R, Orion D, Bruk B, Molshatzki N, Merzeliak O, Chapman J, Tanne D. Ischemic Stroke due to Acute Basilar Artery Occlusion: Proportion and Outcomes. The Israel Medical Association Journal (2010); 12: 671-5
  9. Israeli-Korn SD, Masarwa M, Schechtman E, Strugatsky R, Avni S, Farrer LA, Friedland RP, Inzelberg R. Mild Cognitive Impairment is Associated with Mild Parkinsonian Signs in a Door-to-Door Study of an Elderly Arab Population. J Alzheimers Dis. (2010) 22: 1005-13
  10. Israeli-Korn SD, Masarwa M, Schechtman E, Abuful A, Strugatsky R, Avni S, Farrer LA, Friedland RPInzelberg, R.Hypertension Increases the Probability of Alzheimer’s Disease and of Mild Cognitive Impairment in an Arab Community in Northern Israel. Neuroepidemiology (2010); 34: 99-105
  11. Inzelberg R, Israeli-Korn SD. The particular relationship between Parkinson’s disease and malignancy: a focus on skin cancers. Journal of Neural Transmission (2009); 116: 1503-7
  12. Schwammenthal Y, Tsabari R, Shenkman B, Schwartz R, Matetzky S, Lubetsky A, Orion D, Israeli-Korn S, Chapman J, Savion N, Varon D, Tanne D: Aspirin Responsiveness in Acute Brain Ischaemia: Association with Stroke Severity and Clinical Outcome. Cerebrovasc Dis (2008); 25: 355-361
  13. Howard J, Anie KA, Holdcroft A, Korn S, Davies SC. Cannabis use in sickle cell disease: a questionnaire study. Br J Haematol. (2005); 131: 123-8
  14. Rubinsztein DC, Leggo J, Chiano M, Korn S, Dodge A, Norbury G, Rosser E, Crauford D. Homozygotes and heterozygotes for ciliary neurotrophic factor null alleles do not show earlier onset of Huntingdon’s disease. Neurology (1997); 49: 890-892